Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · November 15, 2023

Selpercatinib for Advanced RET-Mutant Medullary Thyroid Cancer

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

The New England Journal of Medicine
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
N. Engl. J. Med 2023 Oct 21;[EPub Ahead of Print], J Hadoux, R Elisei, MS Brose, AO Hoff, BG Robinson, M Gao, B Jarzab, P Isaev, K Kopeckova, J Wadsley, D Führer, B Keam, S Bardet, EJ Sherman, M Tahara, MI Hu, R Singh, Y Lin, V Soldatenkova, J Wright, B Lin, P Maeda, J Capdevila, LJ Wirth

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated